Company: SMNR
Filing Date: 2025-03-20
Form Type: PRE 14A
Source: 0001213900-25-025610
Chunk: 58

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-20
Form: PRE 14A
Chunk 58
---
 13G, which does not reflect any redemption of shares by Mizuho in connection with extensions of the deadlines to complete the Business Combination or the Business Combination itself, or any other transactions after December 31, 2022. The business address of such holder is 1 -5-5, Otemachi, Chiyoda -ku, Tokyo 100 -8176, Japan. 35 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Class B Ordinary Shares On February 3, 2022, the Sponsor paid an aggregate of $25,000, or approximately $0.012 per share, in consideration of 2,156,250 Class B ordinary shares, par value $0.0001 per share. In March 2022, the Sponsor transferred 20,000 Class B ordinary shares to the Chief Financial Officer of the Company and an aggregate of 110,000 Class B ordinary shares to certain members of the board of directors of the Company. The number of Class B ordinary shares issued was determined based on the expectation that such Class B ordinary shares would represent approximately 20% of the issued and outstanding shares upon completion of the offering (not including the private placement shares). On May 23, 2022, the Sponsor forfeited 93,750 Class B ordinary shares based on the over -allotmentoption partially exercised by the underwriters. On August 30, 2024, the Sponsor and Scilex entered into a sponsor interest purchase agreement (the “Sponsor Interest Purchase Agreement”), pursuant to which Scilex purchased 500,000 Class B ordinary shares (the “Purchased Interests”), that were then -heldby the Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000 (the “Cash Consideration”) and (ii) 300,000shares of common stock, par value $0.0001 per share, of Scilex (the “Scilex Shares”). Pursuant to the Sponsor Interest Purchase Agreement, Scilex paid the Cash Consideration and has agreed to issue the Scilex Shares to the Sponsor contingent upon and following the occurrence of the Effective Time (as defined in the Merger Agreement). The Purchased Interests will convert automatically, on a one -for -onebasis, into shares of common stock of the combined company in a business combination with Semnur at the effective time of the Domestication